Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3519513 | 0.97 | ALOX5 (0.38) | F2ALOX5PTGESTDP2NSD2 | |
| SCHEMBL3517735 | 0.86 | ALOX5 (0.45) | ALOX5PTGESTDP2NSD2PLCG1 | |
| SCHEMBL16275011 | 0.83 | KDM4E (0.39) | F2MAPTALDH1A1HPGD | |
| SCHEMBL3517138 | 0.82 | MEN1 (0.42) | F2MAPTALDH1A1HPGD | |
| SCHEMBL16274613 | 0.81 | KDM4E (0.39) | F2MAPTALDH1A1HPGD | |
| SCHEMBL14306396 | 0.76 | ALOX5 (0.46) | ALOX5PTGESALDH1A1 | |
| SCHEMBL16236700 | 0.76 | MAPK8 (0.38) | MAPTALDH1A1 | |
| SCHEMBL3517692 | 0.75 | KDM4E (0.47) | PTGESMAPTALDH1A1HPGD | |
| SCHEMBL3516004 | 0.73 | ALOX5 (0.48) | ALOX5PTGESALDH1A1 | |
| SCHEMBL3518229 | 0.72 | KDM4E (0.44) | MAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056516-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | MERCK SHARP & DOHME CORP. | 2010-03-04 | — | — | US | disclosed |
| EP-2044068-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | Merck & Co., Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008010964-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | MERCK & CO., INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056516-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | RNASEH1, RNASE1, RNASEL | F2 3148/4885ALOX5 3513/4885PTGES 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.